HighTower Advisors
IOVA icon

HighTower Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

HighTower Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10
Closed -$2K – 3388
2022
Q1 		$2K Buy
+10
New +$155 ﹤0.01% 3342

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

HighTower Advisors's IOVA Position: Q2 2026 in Review

HighTower Advisors opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 14,435 shares worth $60K. The stake represents ﹤0.01% of the portfolio and ranks #3712 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in IOVA as recently as Q4 2025.

HighTower Advisors first reported a position in IOVA in Q2 2019 and has held it in 15 quarters since. The position peaked at $716K in Q3 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • HighTower Advisors held 14,435 shares of Iovance Biotherapeutics worth $60K as of Q2 2026.
  • Iovance Biotherapeutics was a new HighTower Advisors position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3712 holding.
  • HighTower Advisors first reported a position in Iovance Biotherapeutics in Q2 2019 and has held it in 15 quarters since.
  • HighTower Advisors's Iovance Biotherapeutics position peaked at $716K in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.